ADAMTS13—marker of contractile phenotype of arterial smooth muscle cells lost in benign nephrosclerosis

Clemens L. Bockmeyer1,*, Vinzent Forstmeier1,*, Friedrich Modde1, Svjetlana Lovric2, Ralf A. Claus3, Mario Schiffer2, Putri A. Agustian1, Christina Grothusen4, Karsten Grote4, Ingvid Birschmann5, Katharina Theophile1, Hans H. Kreipe1, Verena Bröcker1 and Jan U. Becker1

1Institute of Pathology, 2Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Lower Saxony, Germany, 3Department for Anaesthesiology and Intensive Care Therapy, Friedrich Schiller University Jena, Jena, Thuringia, Germany, 4Department of Cardiology and Angiology and 5Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Lower Saxony, Germany

Correspondence and offprint requests to: Jan U. Becker; E-mail: JanBecker@gmx.com

*These authors contributed equally to this work.

Abstract

Background. Hypertensive nephrosclerosis alone and in combination with other renal diseases is a leading cause of terminal renal insufficiency. Histologic lesions manifest as benign nephrosclerosis (bN) with arteriolar hyalinosis and later fibrosis. Procoagulant micromilieus have been implicated in fibrosis. Hyalinosis is considered to consist of plasma insudation possibly containing procoagulant factors like von Willebrand factor (VWF). Therefore, it is hypothesized that VWF cleaving protease ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type-1 motif, 13) is normally expressed by arteriolar vascular smooth muscle cells (VSMCs) and diminished in bN and that this reduction contributes to fibrosis in bN.

Methods. ADAMTS13 expression was examined by immunohistochemistry and quantitative real-time polymerase chain reaction in VSMCs of various human organs. Fifty-four specimens with and seven without bN were immunostained for ADAMTS13, VWF, CD61 and VSMC differentiation markers in arteriolar walls.

Results. Expression of ADAMTS13 is confirmed in VSMCs. In bN, ADAMTS13 immunostaining of arterial VSMCs correlated inversely with fibrotic but not hyalinotic lesions. Smooth muscle myosin heavy chain showed an inverse correlation with hyalinotic, as opposed to fibrotic lesions of bN. Smoothelin showed an inverse correlation with hyalinotic, as opposed to fibrotic lesions of bN. VWF was absent in normal controls and hyalinotic lesions, but present exclusively in fibrotic lesions in 7/54 (13%) bN cases. CD61 was absent in all arteriolar walls.

Conclusions. The present results establish ADAMTS13 as a novel marker of contractile VSMCs that is retained in early hyalinotic bN but partially lost later in fibrotic bN. Loss of ADAMTS13 and accumulation of VWF in fibrotic

© The Author 2010. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

For Permissions, please e-mail: journals.permissions@oxfordjournals.org
but not hyalinitic arteriolar walls could further propagate fibrosis in bN.

**Keywords:** arterial hypertension; arterioles; hypertensive nephrosclerosis; kidney; sm-MHC

**Introduction**

Hypertensive renal disease is considered the second most common disease leading to end-stage renal failure in the USA [1], although it is argued that clinical data without biopsy verification overestimate the true prevalence [8]. Arterial hypertension is also an important progression factor in other renal diseases, notably diabetic nephropathy [7,12,13,30,38]. Benign nephrosclerosis (bN) is the most prevalent form of hypertensive damage in the kidney and often found in renal biopsies. Characteristic histomorphological findings in bN are hyalinosis, fibrosis, and hypertrophy and kinking of preglomerular vessels. Hyalinosis is predominantly present in the media of the vessel walls [15]. This hyaline has been thought since the times of Fahr to consist of plasma insudation [11,15–17]. Hyalinosis has been described as potentially reversible and is considered to precede fibrosis [15]. Whereas hyalinosis only correlates with tubulointerstitial fibrosis and level and duration of arterial hypertension, fibrosis of small preglomerular vessels is considered the best correlate with glomerular and tubulointerstitial sclerosis, as well as renal function and level and duration of arterial hypertension [20].

Based mainly on studies in the liver, prothrombotic microenvironments have long been implicated in the development of fibrosis [3,50,52]. Among the proteins regulating the coagulation cascade that have been directly linked to the development of liver fibrosis is ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type-1 motif, 13) [46], the cleaving protease of von Willebrand factor-like and metalloprotease with thrombospondin type-1 motif, 13 (ADAMTS13) [46], the cleaving protease of von Willebrand factor.

Expression of ADAMTS13 by VSMCs was confirmed on the mRNA level. TaqMan-based real-time polymerase chain reaction (RT-PCR) was performed after pre-amplification of microdissected VSMCs of normal arteries and arterioles of various human organs, formalin-fixed and paraffin-embedded (FFPE) tissue samples were examined by immunohistochemistry. Organ samples included brain, heart, lung, liver, spleen, pancreas, kidney, renal artery, placenta and also aorta (each n = 3, except for kidney n = 7). All were immunostained for ADAMTS13 using a polyclonal antibody directed against amino acids 1128–1427 of human ADAMTS13 (sc-25584, Santa Cruz Biotechnology, Santa Cruz, CA, USA) after epitope retrieval in Tris/EDTA at pH 9.0 for 20 min at 95°C. The bound primary antibody was visualized with diaminobenzidine (Zytomed Systems, Berlin, Germany) as a substrate for horseradish peroxidase (PolyHRP detection system, Zytomed Systems, Berlin, Germany). Staining was scored as absent, minimal, moderate or strong.

Paraffin sections were immunostained for activated platelets (CD61, C7280, Dako Cytomation, Hamburg, Germany), von Willebrand factor (VWF, M0616, Dako Cytomation, Hamburg, Germany), alpha-smooth muscle actin (alpha-SMA) (M0851, Dako Cytomation, Hamburg, Germany), smooth muscle myosin heavy chain (sm-MHC) (M9850-16X, US-Biologicals, Swampcott, MA, USA) and smoothelin (clone A0483, Abcam, Cambridge, UK). Pretreatment consisted of Protease XXIV digestion for CD61, Pronase (Sigma-Aldrich, Munich, Germany) digestion for VWF and incubation in citrate buffer pH 6.0 at 95°C for 20 min for sm-MHC and smoothelin. Staining was evaluated using the same scoring system as described for ADAMTS13.

For all immunostains, specificity of the primary antibodies was checked by incubation with irrelevant isotype controls (mouse IgG1, #DLN-05792, Dianova, Hamburg, Germany) for monoclonal antibodies (VWF, alpha-SMA, sm-MHC, CD61, smoothelin) and polyclonal rabbit IgG (#DLN-13124, Dianova, Hamburg, Germany) for the polyclonal ADAMTS13 antibody at equivalent concentrations.

**Immunohistochemistry**

In order to establish the expression of ADAMTS13 in VSMCs of normal arteries and arterioles of various human organs, formalin-fixed and paraffin-embedded (FFPE) tissue samples were examined by immunohistochemistry. Organ samples included brain, heart, lung, liver, spleen, pancreas, kidney, renal artery, placenta and also aorta (each n = 3, except for kidney n = 7). All were immunostained for ADAMTS13 using a polyclonal antibody directed against amino acids 1128–1427 of human ADAMTS13 (sc-25584, Santa Cruz Biotechnology, Santa Cruz, CA, USA) after epitope retrieval in Tris/EDTA at pH 9.0 for 20 min at 95°C. The bound primary antibody was visualized with diaminobenzidine (PolyHRP detection system, Zytomed Systems, Berlin, Germany). Staining was scored as absent, minimal, moderate or strong.

Paraffin sections were immunostained for activated platelets (CD61, C7280, Dako Cytomation, Hamburg, Germany), von Willebrand factor (VWF, M0616, Dako Cytomation, Hamburg, Germany), alpha-smooth muscle actin (alpha-SMA) (M0851, Dako Cytomation, Hamburg, Germany), smooth muscle myosin heavy chain (sm-MHC) (M9850-16X, US-Biologicals, Swampcott, MA, USA) and smoothelin (clone A0483, Abcam, Cambridge, UK). Pretreatment consisted of Protease XXIV digestion for CD61, Pronase (Sigma-Aldrich, Munich, Germany) digestion for VWF and incubation in citrate buffer pH 6.0 at 95°C for 20 min for sm-MHC and smoothelin. Staining was evaluated using the same scoring system as described for ADAMTS13.

For all immunostains, specificity of the primary antibodies was checked by incubation with irrelevant isotype controls (mouse IgG1, #DLN-05792, Dianova, Hamburg, Germany) for monoclonal antibodies (VWF, alpha-SMA, sm-MHC, CD61, smoothelin) and polyclonal rabbit IgG (#DLN-13124, Dianova, Hamburg, Germany) for the polyclonal ADAMTS13 antibody at equivalent concentrations.

**Microdissection and quantitative real-time polymerase chain reaction**

Expression of ADAMTS13 by VSMCs was confirmed on the mRNA level. TaqMan-based real-time polymerase chain reaction (RT-PCR) was performed after pre-amplification of microdissected VSMCs of normal renal arteries (n = 3) and umbilical veins (n = 3) as described recently

| Table 1. Quantitative RT-PCR primers. ID # refers to the order number (all supplied by Applied Biosystems, Foster City, CA, USA) |
|-----------------|-----------------|
| **Target transcript** | **TaqMan gene expression assay ID #** |
| A disintegrin-like and metalloprotease with thrombospondin type-1 motif, 13 (ADAMTS13) | Hs00260148_m1 |
| Smooth muscle myosin heavy chain (sm-MHC) | Hs00975778_m1 |
| Alpha-smooth muscle actin (alpha-SMA) | Hs00909449_m1 |
| Smoothelin | Hs00199489_m1 |
| Polymerase II, RNA, subunit A (POLR2A) | Hs01072187_m1 |
| Beta-glucuronidase (GUSB) | Hs99999908_m1 |

**Table 2. Clinical data of the 55 patients with and 7 controls without benign nephrosclerosis (bN)**

<table>
<thead>
<tr>
<th>Age (years)*</th>
<th>Systolic blood pressure (mm Hg)*</th>
<th>Diastolic blood pressure (mm Hg)*</th>
<th>Size (cm)</th>
<th>Body weight (kg)</th>
<th>Body mass index (kg/m²)</th>
<th>Proteinuria*</th>
<th>Serum creatinine (µmol/L)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>54 ± 15.3 (n = 54)</td>
<td>133 ± 27.2 (n = 49)</td>
<td>78 ± 16.5 (n = 49)</td>
<td>175 ± 9.6 (n = 42)</td>
<td>83 ± 16.1 (n = 43)</td>
<td>27.3 ± 5.0 (n = 41)</td>
<td>21/30 (70%)</td>
<td>180 ± 126.9 (n = 41)</td>
</tr>
</tbody>
</table>

*P < 0.05.
Desired cells were isolated from 5-μm sections of FFPE tissue with an MMI microdissector system (Olympus, Hamburg, Germany). RNA was isolated and transcribed into cDNA with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) and then pre-amplified. The primers shown in Table 1 (all Applied Biosystems, Foster City, CA, USA) were mixed with Gene Expression Mastermix (Applied Biosystems, Foster City, CA, USA). TaqMan RT-PCR runs were performed on the 7500 HT (Applied Biosystems, Foster City, CA, USA). For each sample, the ΔCₜ was calculated as Cₜ target − (Cₜ POLRIIa + Cₜ GUSB) / 2, from which the relative expression was calculated as 2⁻ΔCₜ.

Nuclease-free water was used instead of RNA samples as used as negative control [non-template control (NTC)] for cDNA synthesis.

**Human kidney specimens**

To examine the expression of ADAMTS13 in small preglomerular vessels with bn, 51 renal biopsies and tumour-free tissue from three renal cell carcinoma nephrectomies with an isolated diagnosis of bn and without any other vascular, glomerular or tubulointerstitial diseases (total n = 54) were selected from the archives of the Institute of Pathology of the Hannover Medical School. Seven histologically normal renal specimens from tumour nephrectomies (n = 6) and biopsies (n = 1) served as controls. The patients in this control cohort were significantly younger than the patients with bn (P < 0.0001, see Table 2). This could not be avoided since almost all older patients in our archives showed at least minimal bn.

Clinical data were gathered from the files of the respective clinic. Parameters included age, systolic and diastolic arterial blood pressure, body size, body weight, body mass index, proteinuria and serum creatinine.

All renal tissues were examined according to our standard protocol. Hyalinosis and fibrosis of small preglomerular vessels were assigned the following HScore (hyalinosis score) or FScore (fibrosis score): 0 (absent), 1 (minimal), 2 (moderate) and 3 (severe). The two scores were added together for a combined bn grading (bn-grade) defined as 0 (bn-grade absent), 1 to 2 (bn-grade minimal), 3 or 4 (bn-grade moderate) and 5 or 6 (bn-grade severe). In addition, all biopsies were evaluated for the total number of glomeruli, the frequency of globally sclerosed glomeruli and the presence and type of focal segmental glomerulosclerosis (FSGS) (perihilar, cellular, collapsing, tip lesion or not otherwise specified (NOS) as defined by D’Agati et al. [6]). The area ratio of cortical interstitial fibrosis and tubular atrophy (IFTA) to total cortical area was scored as IFTA 0 if <10%, IFTA 1 if <25%, IFTA 2 if <50% and IFTA 3 if ≥50%. ADAMTS13, VWF, alpha-SMA, sm-MHC and smoothelin immunostains were evaluated in small preglomerular vessels as defined by a muscular layer not more than three cells thick and again graded as absent, minimal, moderate or strong.

**Statistical analysis and ethical approval**

Statistical calculations were carried out with Statview (SAS Institute, Cary, NC, USA). For comparison of continuous variables, Mann–Whitney U-tests or Kruskal–Wallis tests were used, and for comparison of nominal variables, chi-squares of Fisher’s exact tests were used. Results were considered as significant with P < 0.05.

All studies were conducted according to the Declaration of Helsinki [2] and were approved by the ethics committee of Hannover Medical School.

**Results**

**ADAMTS13 expression in various human organs**

ADAMTS13 immunohistochemistry. ADAMTS13 had a diffuse cytoplasmic staining pattern in all arterial VSMCs.
Staining intensity was about equal in ECs and VSMCs and was as follows: aorta (2/3 moderate, 1/3 strong), renal artery (2/3 moderate, 1/3 strong, see Figure 1A), parenchymal arteries of spleen (2/3 moderate, 1/3 strong), kidney (5/7 moderate, 2/7 strong, see Figures 1B, 1C and 4D), placenta (3/3 moderate), pancreas (3/3 minimal), lung (1/3 minimal, 2/3 moderate), heart (1/3 minimal, 2/3 moderate), liver (3/3 minimal) and brain (3/3 moderate).

Quantitative RT-PCR of ADAMTS13, sm-MHC, alpha-SMA and smoothelin. Quantitative RT-PCR with RNA isolated from healthy arterial VSMCs confirmed the presence of ADAMTS13 mRNA in arterial VSMCs (see Figures 2 and 3). Relative expression levels of ADAMTS13 (0.06 ± 0.026) were lower than the levels of sm-MHC (317 ± 51.5), alpha-SMA (0.19 ± 0.055) and smoothelin (23 ± 3.6). The NTC gave consistent negative results (see example in Figure 2).

Human kidney specimens

Clinical data. Clinical data of the 54 specimens with bN and the 7 control specimens are given in Tables 2–5. Systolic blood pressure correlated significantly (P = 0.0051) with bN-grade, HScore (P = 0.0013) and FScore (P = 0.0093, see Tables 3–5). Diastolic blood pressure correlated with the presence or absence of bN (see Table 2), HScore (P = 0.0138, see Table 4) and FScore (P = 0.0498, see Table 5).

Serum creatinine correlated significantly with bN-grade (P = 0.0081, see Table 3), HScore (P = 0.0022, see Table 4) and FScore (P = 0.0083, see Table 5).

Conventional light microscopy and bN scoring. All seven normal renal control specimens had HScores and FScores of 0. Among the specimens with bN, the bN-grade had a distribution of 26/54 (48%) minimal, 20/54 (37%) moderate and 8/54 (15%) severe. The distribution of HScores and FScores among all specimens is given in Tables 4 and 5.

The mean frequency of globally sclerosed glomeruli is given in Tables 3–5. BN-grade and HScores did not correlate with the mean frequency of globally sclerosed glomeruli. However, the FScores did (P = 0.0123).
Table 3. Clinicopathological parameters relative to the severity of bN (bN-grade)

<table>
<thead>
<tr>
<th></th>
<th>Absent bN n = 7</th>
<th>Minimal bN n = 26</th>
<th>Moderate bN n = 20</th>
<th>Severe bN n = 8</th>
</tr>
</thead>
<tbody>
<tr>
<td>HScore 0</td>
<td>7/7 (100%)</td>
<td>1/26 (4%)</td>
<td>0/20 (0%)</td>
<td>0/8 (0%)</td>
</tr>
<tr>
<td>HScore 1</td>
<td>0/7 (0%)</td>
<td>22/26 (85%)</td>
<td>5/20 (25%)</td>
<td>0/8 (0%)</td>
</tr>
<tr>
<td>HScore 2</td>
<td>0/7 (0%)</td>
<td>3/26 (11%)</td>
<td>12/20 (60%)</td>
<td>1/8 (12%)</td>
</tr>
<tr>
<td>HScore 3</td>
<td>0/7 (0%)</td>
<td>0/26 (0%)</td>
<td>3/20 (15%)</td>
<td>7/8 (78%)</td>
</tr>
<tr>
<td>FScore 0</td>
<td>7/7 (100%)</td>
<td>13/26 (50%)</td>
<td>0/20 (0%)</td>
<td>0/8 (0%)</td>
</tr>
<tr>
<td>FScore 1</td>
<td>0/7 (0%)</td>
<td>13/26 (50%)</td>
<td>8/20 (40%)</td>
<td>0/8 (0%)</td>
</tr>
<tr>
<td>FScore 2</td>
<td>0/7 (0%)</td>
<td>0/26 (0%)</td>
<td>11/20 (55%)</td>
<td>4/8 (0%)</td>
</tr>
<tr>
<td>FScore 3</td>
<td>0/7 (0%)</td>
<td>0/26 (0%)</td>
<td>1/20 (5%)</td>
<td>4/8 (0%)</td>
</tr>
</tbody>
</table>

IFTA 3* 0/20 (0%) 2/21 (9%) 2/15 (13%) 4/5 (80%)
IFTA 2* 0/20 (0%) 0/21 (0%) 3/15 (20%) 1/5 (20%)
IFTA 1* 4/20 (20%) 9/21 (43%) 3/15 (20%) 1/5 (20%)
IFTA 0* 16/20 (80%) 10/21 (48%) 7/15 (47%) 3/5 (60%)

FSGS 0 ± 0.0% 0 ± 1.1% 0 ± 7.9% 4.0 ± 6.8%
Global glomerulosclerosis 2.4 ± 6.3% 10.3 ± 17.7% 16.1 ± 20.9% 23.0 ± 24.4%

Table 4. Clinicopathological parameters in relation to severity of hyalinosis (HScore)

<table>
<thead>
<tr>
<th></th>
<th>HScore 0 n = 8</th>
<th>HScore 1 n = 27</th>
<th>HScore 2 n = 16</th>
<th>HScore 3 n = 10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic blood pressure (mm Hg)*</td>
<td>106 ± 13.8 (n = 8)</td>
<td>141 ± 24.7 (n = 10)</td>
<td>152 ± 27.4 (n = 9)</td>
<td></td>
</tr>
<tr>
<td>Diastolic blood pressure (mm Hg)*</td>
<td>66 ± 8.7 (n = 8)</td>
<td>84 ± 17.6 (n = 14)</td>
<td>84 ± 15.1 (n = 9)</td>
<td></td>
</tr>
<tr>
<td>Serum creatinine (μmol/L)*</td>
<td>80 ± 22.5 (n = 6)</td>
<td>154 ± 113.6 (n = 13)</td>
<td>308 ± 161.0 (n = 10)</td>
<td></td>
</tr>
<tr>
<td>Global glomerulosclerosis *</td>
<td>3 ± 6.3% (n = 8)</td>
<td>14 ± 19.2% (n = 16)</td>
<td>24 ± 29.1% (n = 10)</td>
<td></td>
</tr>
<tr>
<td>FScore 0</td>
<td>0 ± 0.0%</td>
<td>0 ± 0.0%</td>
<td>0 ± 0.0%</td>
<td>0 ± 0.0%</td>
</tr>
<tr>
<td>FScore 1</td>
<td>8/8 (100%)</td>
<td>7/16 (44%)</td>
<td>3/10 (30%)</td>
<td>1/10 (10%)</td>
</tr>
<tr>
<td>FScore 2</td>
<td>0/8 (0%)</td>
<td>6/16 (38%)</td>
<td>1/10 (10%)</td>
<td>1/10 (10%)</td>
</tr>
<tr>
<td>FScore 3</td>
<td>0/8 (0%)</td>
<td>2/16 (12%)</td>
<td>1/10 (10%)</td>
<td>1/10 (10%)</td>
</tr>
</tbody>
</table>

Table 5. Clinicopathological parameters in relation to severity of arteriolar fibrosis (FScore)

<table>
<thead>
<tr>
<th></th>
<th>FScore 0 n = 20</th>
<th>FScore 1 n = 21</th>
<th>FScore 2 n = 15</th>
<th>FScore 3 n = 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic blood pressure (mm Hg)*</td>
<td>115 ± 17.0 (n = 19)</td>
<td>138 ± 32.7 (n = 12)</td>
<td>157 ± 21.2 (n = 5)</td>
<td></td>
</tr>
<tr>
<td>Diastolic blood pressure (mm Hg)*</td>
<td>69 ± 10.3 (n = 19)</td>
<td>80 ± 25.2 (n = 12)</td>
<td>88 ± 16.8 (n = 5)</td>
<td></td>
</tr>
<tr>
<td>Serum creatinine (μmol/L)*</td>
<td>105 ± 41.0 (n = 18)</td>
<td>195 ± 143.0 (n = 12)</td>
<td>370 ± 158.1 (n = 5)</td>
<td></td>
</tr>
<tr>
<td>Global glomerulosclerosis*</td>
<td>8 ± 15.7% (n = 20)</td>
<td>14 ± 15.9% (n = 15)</td>
<td>40 ± 20.0% (n = 5)</td>
<td></td>
</tr>
<tr>
<td>FScore 0</td>
<td>0 ± 1.3% (n = 20)</td>
<td>2 ± 4.1% (n = 15)</td>
<td>3 ± 7.5% (n = 5)</td>
<td></td>
</tr>
<tr>
<td>FScore 1</td>
<td>16/20 (80%)</td>
<td>7/15 (47%)</td>
<td>0.5 (0%)</td>
<td></td>
</tr>
<tr>
<td>FScore 2</td>
<td>4/20 (20%)</td>
<td>3/15 (20%)</td>
<td>1.5 (20%)</td>
<td></td>
</tr>
<tr>
<td>FScore 3</td>
<td>0/20 (0%)</td>
<td>3/15 (20%)</td>
<td>0.5 (0%)</td>
<td></td>
</tr>
</tbody>
</table>

FSGS was present in 7/54 patients (13%) with bN. FSGS type was perihilar in one specimen with a minimal bN-grade, three with a moderate and one with a severe bN-grade. One single case of FSGS NOS each was present among the patients with moderate and severe bN. The distribution of the frequency of focally and segmentally sclerotic glomeruli is given in Tables 3–5. FSGS was not observed in the control specimens without bN.

The severity score of cortical IFTA also correlated significantly with bN-grade (P = 0.0020, see Table 4). HScore (P = 0.0002, see Table 4) and FScore (P < 0.0001, see Table 5).

Thrombi were found in none of the specimens.

ADAMTS13 immunohistochemistry. Representative examples are depicted in Figure 4D–F, and a comprehensive overview of the results is given in Figure 5A–C. Results
of ADAMTS13 immunostaining of VSMCs in small preglomerular vessels correlated inversely with bN-grades (P = 0.0422, Figure 5A). ADAMTS13 staining of these vessels did not correlate with HScore (see Figure 5B), but correlated inversely with FScores (P = 0.0060, Figure 5C).

**Alpha-SMA immunohistochemistry.** Alpha-SMA was positive only in VSMCs in a diffuse cytoplasmic pattern (representative micrographs in Figure 4G–I). Sm-MHC immunostaining did not show any correlation with bN-grade (see Figure 5D). Sm-MHC staining in VSMCs of small preglomerular vessels correlated inversely with HScores (P = 0.0111, see Figure 5E), but did not correlate with FScores (see Figure 5F).

**Smoothelin immunohistochemistry.** Smoothelin was present in the VSMCs of small preglomerular vessels in a diffuse cytoplasmic pattern also (see Figure 4M–O). The intensity of the immunostaining correlated inversely with bN-grade (P < 0.0001, see Table 5J), HScore (P = 0.0001, see Table 5K) and FScore (P = 0.0119, see Table 5L).

**Additional immunohistochemistry for VWF and CD61.** In order to evaluate the pathophysiological role of ADAMTS13 in bN, all samples were immunostained for activated platelets and VWF. No CD61-positive cells were detected in the subendothelial parts of small preglomerular vessels (see Figure 6) in any of the 54 bN specimens and 7 controls. None of the six control specimens without bN that could be evaluated for VWF immunostaining were positive in the subendothelial space. In contrast, 7/54 (13%) specimens with bN were positive for VWF in the subendothelial space. Notably all hyalinitic lesions were negative for VWF (see Figure 6).

## Discussion

Regulatory proteins of the coagulation system, for example plasminogen activator inhibitor-1, are expressed not only by ECs but also by VSMCs deeper in the arterial wall [5,21,25]. Another example is tissue factor, which can rapidly be induced by injury in arterial VSMCs [28].

The present manuscript adds ADAMTS13 to this list. ADAMTS13 expression has already been confirmed in hepatic stellate cells [47,53] and podocytes [37], both of which are closely related to VSMCs. ADAMTS13 seems to be expressed in VSMCs at an almost equal level throughout the arterial system, in arteries of elastic and muscular type and also in small preglomerular vessels in the kidney. Other members of the ADAMTS family have also been reported in VSMCs. ADAMTS1 has been found in VSMCs of developing mice [41] and also in humans [19]. ADAMTS7 is present in VSMCs of rat carotid arteries and promotes VSMC migration and neointima formation [49].

With the present results, we can only speculate what the (patho-)physiological role of ADAMTS13 expression in VSMCs might be. VWF, the only known substrate of ADAMTS13, is known to be secreted by ECs in arteries not only into the lumen but also into the subendothelial space [36].

Our results support this notion (see Figure 6C). VWF multimers are known to induce intimal fibrosis and VSMC proliferation [33]. It is thus conceivable that ADAMTS13 might cleave and degrade VWF multimers that have permeated into the arterial wall. Since the hyalin deposits in preglomerular vessel walls are thought to consist of plasma insudation through leaky endothelium into the vessel wall [11,15–17], we speculated that this hyaline contained VWF and possibly also platelets. Together they might initiate fibrosis of the vessel wall in hypertension.

Surprisingly, neither VWF nor activated platelets could be found by immunohistochemistry in the hyaline deposits (see Figure 6A–D). Consequently, the hypothesis that diminished production of ADAMTS13 could lead to a procoagulant and thus profibrotic micromilieu via accumulation of ultralarge VWF multimers and activated platelets in the arterial wall is probably incorrect—incorrect at least in the early hyalinotic stage of bN, in which ADAMTS13 immunostaining was preserved. Nevertheless, 13% of the specimens with bN lesions showed VWF immunostaining in the subendothelial compartment of the arteriolar walls exclusively in fibrotic, but not in hyalinitic, lesions, while the normal controls were consistently negative. FScores correlated significantly with decreased immunostaining of VSMCs for VWF cleaving protease ADAMTS13. Taken together, these findings support the hypothesis that a disturbed balance between accumulating VWF multimers and diminished ADAMTS13 might further propagate fibrosis in the later lesions of bN.
Fig. 5. Comprehensive results of ADAMTS13, sm-MHC, alpha-SMA and smoothelin immunostaining of arteriolar VSMCs. HScore, hyalinosis score; FScore, fibrosis score.
VSMCs can acquire contractile or secretory phenotypes [24]. The normal phenotype of VSMCs is contractile, while the secretory phenotype is considered pathologic and contributory to lesions such as atherosclerosis [4,24,35]. It is conceivable that VSMCs of small preglomerular vessels lose their normal contractile phenotype and acquire a secretory phenotype in the progression from normal via hyalinotic to fibrotic lesions of bN. Several marker proteins are known to be characteristic for the normal contractile phenotype, of which we examined alpha-SMA, sm-MHC and smoothelin. Markers that are upregulated in the secretory phenotype are rare, and therefore, this phenotype is generally characterized by the absence of contractile markers [34]. The finding that ADAMTS13 staining is inversely correlated with overall scores of bN and fibrotic type bN, but not with hyalinotic lesions of bN, indicates that ADAMTS13 could be a novel marker of the contractile phenotype of arteriolar VSMCs that is kept in hyalinotic but lost in fibrotic lesions of bN when VSMCs dedifferentiate towards a secretory phenotype and the secreted collagen has already accumulated. Comparison with the established markers of contractile phenotype alpha-SMA [9,18] and sm-MHC [14] showed that alpha-SMA correlated neither with HScores, FScores, now with bN-grade. Consequently, alpha-SMA seems to be an inferior marker of arteriolar VSMC differentiation. Interestingly, analysis of the sm-MHC immunostaining pattern of VSMCs of small preglomerular vessels (see Figure 1G) showed an inverse correlation with HScores but no correlation with FScore or bN-grade. This suggests that sm-MHC could be a marker of acute dedifferentiation in early hyalinotic lesions of bN, which is regained in the chronic, irreversible fibrotic lesions of bN. In this respect, sm-MHC seems to be a complementary marker to ADAMTS13, the loss of which indicates chronic, fibrotic damage. The polyclonal antibody that was used for smoothelin immunostaining recognizes both A and B isoforms. The shorter A isoform is only present in smooth muscle cells of the intestinal muscularis propria [22]. The longer B isoform is only expressed in VSMCs [48]. Smoothelin immunostaining correlated inversely with the severity of both hyalinotic and fibrotic lesions of bN. Therefore, smoothelin is probably the most sensitive marker of the contractile phenotype, with diminished immunostaining even in early, hyalinotic lesions of bN. In this regard, it is superior to ADAMTS13 because diminished smoothelin immunostaining seems to indicate even minor and acute damage to arteriolar VSMCs in bN.
Loss of ADAMTS13 expression in arteriolar VSMCs could also have a direct role in extracellular matrix (ECM) accumulation. It has been speculated that ADAMTS13, as a metalloprotease, might also be involved in ECM degradation [26]. ECM accumulation through diminished degradation in fibrotic lesions of bN with partial loss of ADAMTS13 expression in VSMCs could be a novel pathomechanism in the development of bN. Further insight into additional functions of ADAMTS13 in health and disease could be gained from examination of patients with congenital defects in ADAMTS13 (Upshaw–Schulman syndrome) or from ADAMTS13-knockout mice. Unfortunately, all renal biopsies in our archives from Upshaw–Schulman patients showed severe changes of thrombotic microangiopathy with concomitant malignant nephrosclerosis. No further renal or extrarenal tissue samples could be allocated through inquiries at major German paediatric centres. We are also not aware of any detailed histomorphological description of vessel walls in ‘healthy’ or hypertensive ADAMTS13-knockout mice.

Therefore, it seems premature to ascribe ADAMTS13 a definitive role in ECM degradation, as substrates of ADAMTS13 other than VWF multimers have yet to be established.

A recently published manuscript by Taniguchi et al. links diabetic macroangiopathy and renal diabetic microangiopathy to reduced serum levels of ADAMTS13 [40]. Intravascular ADAMTS13, as measured in the serum, is probably mainly derived from the vascular endothelium as our immunohistochemical stains support (see Figure 1). Endothelial dysfunction in diabetes could lead to decreased secretion of ADAMTS13. Diminished intravascular levels of ADAMTS13 could then cause microthrombi in the intravascular compartment. Indeed,glomerular microthrombi have been reported in a substantial number of biopsies with diabetic glomerulopathy [31]. In contrast to Taniguchi’s work, the present manuscript addresses ADAMTS13 expressed by VSMCs. ADAMTS13 derived from VSMCs probably remains in the media and therefore should not contribute significantly to serum levels of ADAMTS13 and should have no antithrombotic effects within the intravascular compartment. In support of this, we did not observe any intravascular thrombi nor are there any literature reports of thrombi in bN known to us. Nevertheless, additional studies could potentially clarify whether ADAMTS13 serum levels are diminished in patients with bN.

Conclusion

In summary, it is proven for the first time that ADAMTS13 is expressed in arterial and arteriolar VSMCs throughout the human organism. The role of ADAMTS13 expression in VSMCs is probably cleavage of endothelium-derived VWF multimers permeating into the arterial walls. ADAMTS13 can be considered a marker of the contractile phenotype that is lost in the chronic, fibrotic lesions of bN. Loss of ADAMTS13 and accumulation of VWF exclusively in fibrotic arteriolar lesions could contribute to fibrosis propagation in bN.
ADAMTS13—marker of contractile phenotype of arteriolar VSMCs


32. Plaimauer B, Zimmermann K, Volkel D. ADAMTS13—marker of contractile phenotype of arteriolar VSMCs


Received for publication: 14.4.10; Accepted in revised form: 9.9.10